Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Republic By: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0554-89 (carton) and 00182-0554-00 (single blister).

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Recall #: D-1074-2014
Affected scope: 1,249,700 tablets
Initiated: December 18, 2013

Compiled from official public sources by the publisher. · Updated September 2026

Verify with FDA Drug →

View my saved recalls

Teva Pharmaceuticals USA recalled Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Re… - a moderate-severity action.

Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Re… was recalled by Teva Pharmaceuticals USA in February 12, 2014. Reason: Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification …. Check the official notice for the remedy. Verify recall #D-1074-2014 with the FDA Drug before acting.

The recall

Teva Pharmaceuticals USA issued this moderate-severity FDA Drug recall-Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification ….

Moderate
severity level: Class II
classification: February 12, 2014
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1074-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Republic By: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0554-89 (carton) and 00182-0554-00 (single blister).

Reason for recall

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Terminated
Recall number	D-1074-2014
Date reported	February 12, 2014
Date initiated	December 18, 2013
Recalling firm	Teva Pharmaceuticals USA
Firm location	Horsham, PA
Affected scope	1,249,700 tablets
Distribution	Nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-1074-2014) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on February 12, 2014. Severity: Moderate. Recall number: D-1074-2014.

Where was the recalled product distributed? ▼

Distribution: Nationwide.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

Visonic Amber Personal Emergency Response… 2014-02-12 Air Compressors Recalled by MAT Industrie… 2014-02-12 Dicopanol FusePaq Kit for Oral Suspension… 2014-02-12 Cornea Coat, Hydroxypropylmethylcellulose… 2014-02-12

Similar Household Products · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Christmas Lights Recalled by Pepe Ganga D… 2014-02-07 Sterling Rope Company Recalls Sewn Cords … 2014-02-20 Eastman Footwear Recalls Coleman Runeston… 2014-02-20 Lion Force Recalls Boys’ Puffer Coats Due… 2014-02-04

Compare this recall with CCM Hockey U.S. Recalls FMHVR Hybrid Visors and ACCHVR Repl… → · All Household Products recalls

This recall: FDA Drug, reported February 12, 2014. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026